bempikibart

Q32 Bio Reports Positive Phase 2 Results for Investigational Treatment for Severe to Very Severe Alopecia Areata in Adults

Q32 Bio has announced positive 36-week topline results from Part B of its Phase 2 SIGNAL-AA clinical trial evaluating bempikibart,…